| 0.6288 0.043 (7.29%) | 03-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.75 | 1-year : | 0.87 |
| Resists | First : | 0.64 | Second : | 0.75 |
| Pivot price | 0.59 |
|||
| Supports | First : | 0.57 | Second : | 0.52 |
| MAs | MA(5) : | 0.6 |
MA(20) : | 0.58 |
| MA(100) : | 0.56 |
MA(250) : | 0.6 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 71.1 |
D(3) : | 64.3 |
| RSI | RSI(14): 57.6 |
|||
| 52-week | High : | 0.96 | Low : | 0.36 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SESN ] has closed Bollinger Bands are 27.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.63 - 0.63 | 0.63 - 0.64 |
| Low: | 0.56 - 0.57 | 0.57 - 0.57 |
| Close: | 0.62 - 0.63 | 0.63 - 0.63 |
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Tue, 02 Apr 2024
SESEN BIO, INC. (SESN) Dips More Than Broader Markets: What You Should Know - Yahoo Movies Canada
Tue, 07 Mar 2023
Carisma Therapeutics Closes Merger with Sesen Bio - PR Newswire
Thu, 02 Mar 2023
Sesen Bio Stockholders Approve Merger with Carisma Therapeutics - Business Wire
Mon, 06 Feb 2023
Sesen Bio (NASDAQ:SESN) investors are sitting on a loss of 37% if they invested three years ago - Yahoo Finance
Mon, 30 Jan 2023
Sesen Bio Receives NASDAQ Delisting Notice - Business Wire
Wed, 21 Sep 2022
Novartis, Moderna Partner Agrees To Merge With Beleaguered Sesen Bio - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 203 (M) |
| Shares Float | 187 (M) |
| Held by Insiders | 8.8 (%) |
| Held by Institutions | 12.8 (%) |
| Shares Short | 3,200 (K) |
| Shares Short P.Month | 2,890 (K) |
| EPS | -0.2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.08 |
| Profit Margin | -5.7 % |
| Operating Margin | -43.3 % |
| Return on Assets (ttm) | -7.5 % |
| Return on Equity (ttm) | -2.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.29 |
| EBITDA (p.s.) | -0.13 |
| Qtrly Earnings Growth | -71.5 % |
| Operating Cash Flow | 10 (M) |
| Levered Free Cash Flow | 24 (M) |
| PE Ratio | -3.3 |
| PEG Ratio | 0 |
| Price to Book value | -8.99 |
| Price to Sales | 2.12 |
| Price to Cash Flow | 13.26 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|